OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Damodaran on the ELAINE-2 Trial of Lasofoxifene/Abemaciclib in ESR1-Mutated, ER+/HER2- Breast Cancer

September 19th 2022

Senthil Damodaran, MD, PhD, discusses data from the phase 2 ELAINE-2 trial examining the combination of lasofoxifene and abemaciclib in patients with ESR1-mutated, estrogen receptor–positive/HER2-negative metastatic breast cancer.

Dr. Gutierrez on the Investigation of MK-0482 in Advanced Solid Tumors

September 16th 2022

Martin E. Gutierrez, MD, discusses the investigation of MK-0482 in advanced solid tumors.

Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

September 16th 2022

Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.

Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast Cancer

September 16th 2022

Madhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.

Dr. Goy on Updates in Precision Medicine in Hematologic Malignancies

September 15th 2022

Andre H. Goy, MD, discusses updates in precision medicine.

Dr. Ip on the Utility of Carboplatin, Pemetrexed, and Pembrolizumab in Lung Adenocarcinoma

September 15th 2022

Andrew Ip, MD, discusses carboplatin, pemetrexed, and pembrolizumab as first-line therapy in recurrent/metastatic non–small cell lung cancer.

Dr. McCloskey on the Efficacy of CPX-351 in FLT3-Mutated AML

September 15th 2022

James K. McCloskey, MD, discusses the efficacy of CPX-351 in FLT3-mutated acute myeloid leukemia.

Dr. Verstovsek on Pemigatinib in FGFR1-Rearranged Myeloid Neoplasms

September 14th 2022

Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.

Dr. Modi on Trastuzumab Deruxtecan in HER2-low Breast Cancer

September 14th 2022

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

Dr. DiSilvestro on 7-Year Follow up of Olaparib Maintenance in Advanced Ovarian Cancer

September 12th 2022

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

Dr. Strickler on the Results of Tucatinib Monotherapy in HER2+ CRC

September 12th 2022

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

Dr. Patel on the Neoadjuvant Administration of Pembrolizumab in Advanced Melanoma

September 11th 2022

Sapna Patel, BA, MD, discusses the neoadjuvant administration of pembrolizumab in advanced melanoma.

Dr. Petrylak on Enzalutamide Plus Androgen Deprivation Therapy in mHSPC

September 11th 2022

Daniel P. Petrylak, MD, discusses enzalutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer.

Dr Allaf on Perioperative Nivolumab Vs Observation Following Nephrectomy in RCC

September 10th 2022

Mohamad Ezzeddine Allaf, MD, discusses the results of perioperative nivolumab vs observation in patients with renal cell carcinoma who undergo nephrectomy.

Dr. Ornstein on Toxicity Concerns for Neoadjuvant Therapy in Localized RCC

September 9th 2022

Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.

Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL

September 9th 2022

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Dr. Yarchoan on Gemcitabine and Cisplatin Combination Therapy Biliary Tract Cancer

September 8th 2022

Mark Yarchoan, MD, discusses the addition of durvalumab (Imfinzi) to gemcitabine and cisplatin in biliary tract cancer.

Dr. Martin-Broto on Future Research Directions of Soft Tissue Sarcoma

September 8th 2022

Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.

Dr. Conlin on the Practice-Changing Data of Trastuzumab Deruxtecan in HER2+ Breast Cancer

September 7th 2022

Alison K. Conlin, MD, discusses the practice-changing data of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Shah on Evaluating AUTO1 in Relapsed/Refractory B-Cell ALL

September 7th 2022